Browse Studies — Arctuva

Phase 2

An Open-Label Study to Assess the Safety and Efficacy of Remdesivir for Treatment of Symptomatic Laboratory-Confirmed Respiratory Syncytial Virus Infection of the Upper Respiratory Tract in High-Risk Immunocompromised Patients

This phase II trial tests how well remdesivir works for treatment of respiratory syncytial virus (RSV) infection of the upper respiratory tract in patients rec…

Hematopoietic and Lymphatic System NeoplasmAutoimmune DiseaseRespiratory Syncytial Virus Infection

Estimated

~$10 – $6,250

Fred Hutchinson Cancer CenterNCT06817889

Phase 1

A Phase 1/2, Randomized, Controlled, Observer-blind, Multicentre Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of GSK Biologicals' Investigational Respiratory Syncytial Virus (RSV)/Human Metapneumovirus (hMPV) Combination and Investigational hMPV Vaccines When Administered Intramuscularly According to a Single Dose Schedule in Younger Adults ≥18 to ≤49 Years and Older Adults Aged ≥60 to ≤80 Years

The aim of this study is to evaluate the safety, reactogenicity, and immune response of the different formulations of the investigational RSV/hMPV combination …

Respiratory Syncytial Virus Infections+Metapneumovirus

Estimated

~$10 – $7,500

GlaxoSmithKlineNCT07628049

Phase 2

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety, Tolerability, and Efficacy of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus Who Are at High Risk of Progression to Severe Disease

The main purpose of this study is to investigate the antiviral effect of S-337395 compared with placebo among nonhospitalized adult participants with high-risk…

Respiratory Syncytial Virus Infections

Estimated

~$10 – $7,500

ShionogiNCT07214571

Phase 1

A Phase 1/2a Trial of the Safety, Tolerability and Immunogenicity of PIV5-vectored RSV Vaccine (BLB-201) in RSV Seronegative and Seropositive Infants and Children

This Phase 1/2a trial is a randomized, placebo-controlled trial to evaluate the safety, tolerability and immunogenicity of two ascending doses (10\^6 PFU and 1…

Respiratory Syncytial Virus Infections

Estimated

~$10 – $8,750

Blue Lake Biotechnology Inc.NCT05655182

Phase 3

Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children

The overarching hypothesis of the ARRC trial is that administration of Azithromycin (AZM) during acute, Respiratory Syncytial Virus (RSV)-induced respiratory f…

Respiratory Syncytial Virus Infections

Estimated

~$10 – $6,250

University of Alabama at BirminghamNCT05026749